“Over the past several months we’ve achieved significant regulatory and clinical milestones while adding $5.5 million to the balance sheet, paving the way for an exciting 2024 marked by key data readouts. Our Phase 2a biomarker study for GRI-0621 in IPF is gaining momentum and with interim and topline data expected this year, we believe we have the potential to unlock substantial value for all stakeholders,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
- GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
- GRI Bio announces notice of allowance for Canadian patent
- GRI Bio receives MRHA authorization to conduct Phase 2a study of GRI-0621
- GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
